Edge Rewrite
// HTMLRewriter · presentation

This page was redesigned at the edge.

Cloudflare fetched the original article and streamed it through HTMLRewriter to apply an entirely new visual system without rebuilding the source page.

// request.cf · coarse context

A page that knows where it met you.

Only coarse request metadata is shown. This demo does not display or persist visitor IP addresses.

Country
US
Cloudflare location
CMH
Connection
HTTP/2
Language
Not provided

Ray ID: a25e2788ec1618aa

Jump to content

// Workers AI · dad joke modeWhat did CT-4201 say to CT-4202? You're one greater.

From Wikipedia, the free encyclopedia

CT-4201
Clinical data
Other namesCT4201
Drug classNon-selective serotonin receptor agonist; Serotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen
ATC code
  • None

CT-4201 is a serotonergic psychedelic which is under development for the treatment of major depressive disorder.[1][2][3] It is a prodrug of the tryptamine psychedelic psilocin that is said to have improved pharmacokinetic properties compared to psilocybin, the primary active constituent of psilocybin-containing mushrooms.[1][2][3][4][5] CT-4201 is being developed by CaaMTech.[1][2][3] As of November 2024, it is in the preclinical research stage of development.[1][2]

See also

[edit]

References

[edit]
  1. 1 2 3 4 "Delving into the Latest Updates on CT-4201 with Synapse". Synapse. 8 May 2025. Retrieved 1 August 2025.
  2. 1 2 3 4 Haichin M. "Psychedelics Drug Development Tracker". Psychedelic Alpha. Retrieved 1 August 2025.
  3. 1 2 3 "FDA Endorses CaaMTech's Psilocin Drug Development For Depression Treatment". Sahm. 14 November 2024. Retrieved 1 August 2025.
  4. "CaaMTech receives FDA endorsement for psilocin depression drug development". SPEEDA Edge. 14 November 2024. Retrieved 1 August 2025.
  5. "CaaMTech Receives Regulatory Validation for Functional Unblinding Strategy in Psilocin Prodrug Trial". MedPath. 15 November 2024. Retrieved 1 August 2025.